Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients
British Journal of Haematology · 2024
DOI: 10.1111/bjh.19874 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Hayley Colton und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, SARS-CoV-2, Antibodies, Neutralizing, COVID-19. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Birmingham, The Danson Foundation, Huo Family Foundation.
Abstract (Originalsprache)
Whilst SARS‐CoV‐2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T‐cell (CAR‐T) recipients respond poorly. HSCT/CAR‐T treatment ablates existing immune memory, with recipients requiring revaccination analogous to being vaccine naive. An optimal revaccination strategy for this cohort has not been defined. Factors predicting immunogenicity following three ancestral SARS‐CoV‐2 vaccines were assessed in 198 HSCT/CAR‐T recipients and 96 healthcare workers (HCWs) recruited to multicentre studies. Only 25% of HSCT/CAR‐T recipients generated nAbs following one dose, with titres 167‐fold and 7‐fold lower than that in HCWs after the first and second doses, respectively. Lower post‐second dose nAb titres were associated with older age, rituximab use, and previous HSCT. ChAdOx1‐S recipients were more likely to generate nAbs compared with mRNA vaccines, with titres comparable to HCWs. In contrast, nAbs were significantly lower in HSCT/CAR‐T recipients than HCWs after mRNA vaccination. The poor first‐dose immunogenicity in HSCT/CAR‐T recipients suggests a minimum licensed dosing interval could limit the period of vulnerability following HSCT/CAR‐T. The relative preservation of nAbs with ChAdOx1‐S vaccination highlights the importance of evaluating alternative platforms to mRNA vaccination within this highly vulnerable clinical cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Medicine, School of Medicine and Population Health, The University of Sheffield, Sheffield, UK.
- NIHR Sheffield Biomedical Research Centre and the Florey Institute of Infection, University of Sheffield, Sheffield, UK.
- Viral Pseudotype Unit, Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, UK.
- Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK.
- Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
- College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK.
ORCID-Profile: Hayley Colton, Pamela Kearns, Paul Miller, Robin Sanderson, John A Snowden
Förderung
- University of Birmingham
- The Danson Foundation
- Huo Family Foundation
- NIHR Southampton Clinical Research Facility
- Blood Cancer UK
- IMPACT consortium
- Cancer Research UK
- Sheffield Teaching Hospitals NHS Foundation Trust
Zitieren
APA
Colton, H., Barratt, N., Temperton, N., Hornsby, H., Angyal, A., Grouneva, I., Lindsey, B. B., Kearns, P., Barnes, E., Goodyear, C. S., Richter, A., Thomas, D., Cook, G., McInnes, I. B., Willicombe, M., Siebert, S., Orchard, K., Selby, R., Bowden, S., …, & de Silva, T. I. (2024). Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology. https://doi.org/10.1111/bjh.19874
Vancouver
Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, et al. Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology. 2024. doi:10.1111/bjh.19874
BibTeX
@article{Colton2024,
author = {Colton, Hayley and Barratt, Natalie and Temperton, Nigel and Hornsby, Hailey and Angyal, Adrienn and Grouneva, Irina and Lindsey, Benjamin B and Kearns, Pamela and Barnes, Eleanor and Goodyear, Carl S and Richter, Alex and Thomas, David and Cook, Gordon and McInnes, Iain B and Willicombe, Michelle and Siebert, Stefan and Orchard, Kim and Selby, Rachael and Bowden, Sarah and Collini, Paul J and Pope, Ann and Kirkham, Amanda and Kronsteiner, Barbara and Dunachie, Susanna J and Miller, Paul and Clay, Jennifer and Hurst, Erin and Malladi, Ram and Kesavan, Murali and Kinsella, Francesca and Sanderson, Robin and Yong, Kwee L and Rea, Daniel and Parry, Helen and PITCH Consortium, OCTAVE Collaborative Group, OCTAVE‐DUO Investigators, PROSECO Investigators, PITCH Consortium, OCTAVE Collaborative Group, OCTAVE‐DUO Investigators, PROSECO Investigators and Lim, Sean H and Snowden, John A and de Silva, Thushan I},
title = {Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients},
journal = {British Journal of Haematology},
year = {2024},
doi = {10.1111/bjh.19874}
}
EUVIMED